1985
Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate
Trigg M, Makuch R, Glaubiger D. Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. International Journal Of Radiation Oncology • Biology • Physics 1985, 11: 699-702. PMID: 3838542, DOI: 10.1016/0360-3016(85)90300-1.Peer-Reviewed Original ResearchConceptsEwing's sarcomaIntrathecal methotrexateCNS irradiationProphylactic cranial irradiationGroup of patientsCurrent treatment regimensLack of efficacyNational Cancer InstituteCranial irradiationInitial therapyCNS involvementCNS recurrenceTreatment regimensCNS treatmentIrradiation regimenCancer InstituteActuarial riskSarcomaOverall riskPatientsTherapyMethotrexateRiskCNSInvolvement
1983
Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapse
1982
Adjusted survival curve estimation using covariates
Makuch R. Adjusted survival curve estimation using covariates. Journal Of Clinical Epidemiology 1982, 35: 437-443. PMID: 7042727, DOI: 10.1016/0021-9681(82)90058-3.Peer-Reviewed Original Research
1981
Influence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
1980
Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma
Glaubiger D, Makuch R, Schwarz J, Levine A, Johnson R. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45: 2213-2219. PMID: 7370962, DOI: 10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrognostic factorsEwing's sarcomaTreatment groupsLactic acid dehydrogenasePrimary diseaseSerum lactic acid dehydrogenaseSystemic chemotherapy regimensFavorable prognostic factorTime of presentationLactic acid dehydrogenase levelsNumber of patientsResults of treatmentNational Cancer InstituteLatest regimensChemotherapy regimensMetastatic diseaseFavorable prognosisMetastatic statusFavorable outcomeTherapeutic resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer Institute